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CASE REPORT
About 60 years ago, Wiskott first described three
boys with classical symptoms of Wiskott-Aldrich
syndrome (WAS), which included bleeding due
to thrombocytopenia, eczema, and frequent in-
fections.1 In the past decades, it has been found
that WAS is an X-linked inherited immuno-
deficiency caused by a variety of mutations in 
the gene encoding the WAS protein (WASP).2
WASP is linked to the regulation of cell signaling
and cytoskeleton reorganization in hematopoietic
and immune systems.3,4 The high morbidity and
early mortality in patients with WAS are frequent-
ly associated with bleeding or recurrent infec-
tions, including pyogenic, viral and opportunistic
infections.5
Cytomegalovirus (CMV) is a member of the
herpes virus family. Most patients with CMV 
infections are asymptomatic or only have mild
disease.6 However, immunocompromised chil-
dren who experience CMV infection are at risk
for developing disseminated diseases that may
be fatal.7 In this report, we present a case of WAS
complicated with fatal CMV disease.
Case Report
The patient was the first son of healthy parents,
born at term following an uncomplicated preg-
nancy, and his body weight at birth was 2810 g.
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Although most cytomegalovirus (CMV) infections are asymptomatic or cause only mild disease, the virus
can cause serious disease and even mortality in immunocompromised children. In patients with Wiskott-
Aldrich syndrome (WAS), recurrent CMV infection is infrequently seen. A 3-month-old male infant was re-
ferred to Chang Gung Children’s Hospital due to persistent thrombocytopenia and intermittent tachypnea.
WAS complicated with CMV pneumonitis was diagnosed subsequently. He was discharged at the age of 
7 months after a complete course of antiviral treatment. Unfortunately, refractory hemorrhagic gastritis
developed later and recurred in spite of antiviral treatment and intravenous immunoglobulin. The patient
died of recurrent gastrointestinal bleeding at the age of 23 months. This observation indicates that a case
of WAS complicated with CMV gastrointestinal disease may need more vigorous treatment. [J Formos Med
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General petechiae and thrombocytopenia (plate-
let count, 5200/µL) were noted at the age of 18
days. There was no family history of hematologic
disorders.
At the age of 3 months, he was referred to
Chang Gung Children’s Hospital because of per-
sistent thrombocytopenia and intermittent tachy-
pnea. On examination, he looked well and was
not icteric. He had no lymphadenopathy or 
hepatosplenomegaly, and the positive findings
were general petechiae and eczema. Initial labo-
ratory study results were: white blood cell count,
14,600/µL; red blood cell count, 3.62 × 106/µL;
hemoglobin, 10.3 g/dL; platelet count, 13,000/µL;
and serum C-reactive protein, 121.6 mg/L. Alanine
transaminase, sugar and electrolytes were normal.
Tiny platelets were found on peripheral blood
smear. Bone marrow study revealed a cellular
marrow with active hematopoiesis and no ab-
normal cell infiltration. Serum immunoglobulin
levels were: immunoglobulin (Ig) G, 2270 mg/dL;
IgA, 154 mg/dL; IgM, 131 mg/dL; IgE, 2030 IU/mL;
IgD, < 42.53 IU/mL. The relative proportions of
immune cells were CD3 48.7%, CD4 27.7%,
CD8 6.3% and CD19 3.2%. Pokeweed mitogen
test was not performed. However, genetic analy-
sis using polymerase chain reaction revealed a
large deletion in the WASP gene that encom-
passed the promoter, exon 1 and exon 2, result-
ing in an aberrant WASP product that was not
recognized by polyclonal WASP antibody.8
After admission, intermittent tachypnea and de-
saturation were noted. Chest radiography showed
mild and nonspecific perihilar infiltrates in both
lungs. Viral serology study showed a positive re-
sult for CMV IgM. CMV was subsequently identi-
fied by a urine shell vial culture method and from
the throat swab. CMV antigenemia was also found
(14 positive cells per 500,000 neutrophils).
Administration of intravenous ganciclovir (10 mg/
kg/day) was started. When he was 5 months old,
during the maintenance therapy phase (5 mg/kg/
day, 5 days/week), he required ventilatory support
due to aggravated tachypnea and desaturation.
Chest radiography showed diffuse alveolar opac-
ities in both lungs at this point. CMV antigenemia
continued to persist and even elevated (62 positive
cells per 500,000 neutrophils). The dosage of in-
travenous ganciclovir was elevated to 10 mg/kg/day
in addition to the administration of four doses
of CMV hyperimmune globulin. His condition
gradually improved and he was extubated 6 days
later. He was discharged from our hospital at the
age of 7 months without prophylactic antibiotics.
At the age of 11 months, he began to have 
recurrent episodes of hematemesis and melena
despite regular transfusions of irradiated platelets,
and was admitted to our hospital frequently due 
to massive gastrointestinal bleeding; resultant hy-
povolemic shock occasionally developed. A series
of panendoscopies were performed. Duodenal
ulcers and diffuse hemorrhagic gastritis with ero-
sions over the gastric body and antrum were
found initially. Urease enzyme test was negative
and no Helicobacter pylori was found on stomach
biopsy. At the age of 19 months, he had a similar
episode of upper gastrointestinal bleeding. CMV
inclusion bodies were seen in the gastric biopsy
specimen at this point and CMV antigenemia 
(4 positive cells per 500,000 neutrophils) was
noted simultaneously (Figure). He received intra-
venous ganciclovir therapy again. CMV antigene-
mia subsided but was detected intermittently.
During hospitalization, he also developed sev-
eral episodes of methicillin-resistant Staphylococcus
aureus bacteremia secondary to either soft tissue
infection or pneumonia, despite the monthly 
administration of prophylactic treatment with
intravenous IG (IVIG) that had been initiated
since the age of 15 months.
The patient’s condition continued to deteriorate
despite ganciclovir therapy, blood transfusion,
and IVIG infusion. Bradycardia and hypotension
occurred following massive hematemesis, and
under the family’s agreement of do-not-resuscitate,
the patient died at the age of 23 months.
Discussion
WAS is a rare congenital disorder that has been a
challenge for clinicians and scientists for almost
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a century. Nevertheless, according to the data per-
taining to the natural history of WAS, recurrent
CMV infection is infrequently seen.5 However,
Kaneko et al did report that a boy with WAS suf-
fered from recurrent CMV pneumonia under
prophylactic antibiotic.9
The only curative choice for the WAS patient
in the long run is stem cell transplantation. In our
patient, the hematologist in our hospital hesi-
tated to perform stem cell transplantation due to
the consideration that the CMV infection might
be aggravated once the patient is put on immuno-
suppressive agents after transplantation. At pres-
ent, in addition to stem cell transplantation, some
conventional treatment strategies and the use 
of prophylactic antibiotics, IVIG, splenectomy or
platelet transfusion are also effective in prevent-
ing the morbidities and expanding the lifespan
of WAS patients.10,11
Infants can acquire CMV infection from other
children or from their mothers in utero, at birth,
during the perinatal or postnatal period.12 The
acquisition of CMV in this case might have been
early in life, either in the perinatal or early post-
natal period. Although no specific actions can to-
tally eliminate the risks of getting CMV infection,
enhancement of the caregiver’s personal hygiene
and appropriate isolation from other children
may be possible strategies for WAS patients.
Primary CMV infection, reactivation of latent
infection or re-infection by a novel exogenous
strain may involve the gastrointestinal tract in im-
munocompromised patients, especially in patients
with AIDS, and ulcerated lesions with resultant
bleeding are usually seen.13,14 In this patient, the
condition was more complicated. In addition to
CMV gastritis and ulcers, predisposing thrombo-
cytopenia may contribute to prolonged, recurrent
and life-threatening gastrointestinal bleeding. The
optimal treatment protocol for such a complicated
condition is not yet clear. A previous study in AIDS
patients demonstrated that both ganciclovir and
foscarnet are effective for mucosal healing in CMV
gastrointestinal disease.15 Ganciclovir seemed to be
ineffective for CMV gastrointestinal disease in this
patient and a second-line drug such as foscarnet,
which is not available in Taiwan, or a combination
of antiviral treatment may have led to a better
outcome.16–18 Management of thrombocytopenia-
induced life-threatening bleeding was another
major issue in this patient. Splenectomy is usu-
ally effective in increasing platelet numbers and
reducing bleeding complications, but also in-
creases the risk of infection in WAS patients.11
This patient did not present with splenomegaly
and so did not receive splenectomy. However, 
if stem cell transplantation is not feasible, then
splenectomy might be the treatment of choice.
We have described a case of WAS complicated
with CMV pneumonitis and gastritis. A fatal out-
come occurred due to refractory CMV gastrointesti-
nal disease with recurrent bleeding. Although the
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Figure. (A) Gastric mucosa biopsy specimen shows mild lymphoplasmacytic infiltration and a characteristic intranuclear
inclusion-bearing cell (arrow) (hematoxylin & eosin, original magnification 400×). (B) Positive immunohistochemistry
stain for cytomegalovirus (arrow) (original magnification 100×).
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only curative choice for the WAS patient in the
long run is stem cell transplantation, a consen-
sus concerning the management of such patients
prior to transplantation should be established.
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